Theravance Biopharma, Inc.

Theravance Biopharma, Inc. ( we, our, Theravance Biopharma or the Company ) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. Our focus is to deliver medicines that make a difference in people’s lives. In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States ( US ) Food and Drug Administration (the FDA ) approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease ( COPD ). Recent Significant Developments Ampreloxetine Phase 3 Clinical Study Top-line Results On March 3, 2026, we announced that our ampreloxetine Phase 3 clinical study (CYPRESS) in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score. As a result of this outcome, we have decided to wind down the ampreloxetine program. Strategic Review Committee In connection with the CYPRESS study results, the Strategic Review Committee of our Board of Directors (the "Committee") is accelerating its ongoing review of alternatives to maximize value for shareholders. Since its formation in 2024, the Committee has been working on an ongoing basis with Lazard, its independent financial advisor, to evaluate opportunities available to the Company, including under multiple potential outcomes for the CYPRESS study.